Acute Ischemic Stroke: Global Drug Forecast and Market Analysis to 2027

Wednesday, November 7, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Nov. 6, 2018 /PRNewswire/ -- Acute Ischemic Stroke: Global Drug Forecast and Market Analysis to 2027SummaryRead

the full report: https://www.reportlinker.com/p05609225 Sales of drugs in the AIS market (including TIA) were approximately $7.2B in 2017 in the 8MMthe US, five major European countries (5EU: France,
Germany, Italy, Spain, and the UK), Japan, and China. The US was the largest market, with sales of $3.4B, representing 47% of all sales from the 8MM. The highest-selling drug in the market was Roche's Activase (alteplase), which generated sales of $1.2B in the 8MM in 2017.Stroke is caused by the interruption of the blood supply to the brain, usually because a cerebral blood vessel ruptures and bleeds (hemorrhagic stroke) or is blocked by a clot (ischemic stroke), which obstructs blood flow and oxygen and nutrients from reaching the brain, causing death of the local brain tissue (infarction). Stroke is a leading cause of disability and death worldwide and a common cause of dementia, associated with significant social and economic impact.The Acute Ischemic Stroke (AIS) market is about to enter an exciting phase over the next decade with novel therapies entering the market that are designed to improve stroke outcome. Global sales in the Acute Ischemic Stroke (AIS) market are expected to growat a compound annual growth rate (CAGR) of 3.9% till 2027. The main drivers of growth will be the launch of three novel neuroprotective agents (NA-1, BIIB093, and 3K3A-APC) and one stem cell therapy (MultiStem) aimed at improving clinical outcome post-stroke when given in the acute phase of stroke, along with Activase or endovascular treatment (EVT) or both. One stem cell therapy, SB623, is designed to reduce disability in patients with chronic stroke, potentially given years after the initial event."Acute Ischemic Stroke: Global Drug Forecast and Market Analysis to 2027", report helps in some very specific question of the Acute Ischemic Stroke (AIS) Market.They are -- What are the key drivers of significant growth of the Acute Ischemic Stroke (AIS) market?- What are the pricing and reimbursement prospects for the upcoming novel therapies?- What is the market potentials of drugs developed for the treatment of Acute Ischemic Stroke (AIS), and would they fulfill the greatest unmet needs in this space?- How will key patent expiries of novel anticoagulants (NOACs) impact sales of current and launching therapies in Acute Ischemic Stroke (AIS)?- Will there be opportunities remaining after the launch of late pipeline drugs in Acute Ischemic Stroke (AIS)?Scope- Overview of AIS, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.- Annualized AIS therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for ten years to 2022.- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the AIS therapeutics market.- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.- Analysis of the current and future market competition in the global AIS therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.Reasons to buyThe report will enable you to -- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.- Develop business strategies by understanding the trends shaping and driving the global AIS therapeutics market.- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AIS therapeutics market in the future.- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.Read the full report: https://www.reportlinker.com/p05609225 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Cision View original content:http://www.prnewswire.com/news-releases/acute-ischemic-stroke-global-drug-forecast-and-market-analysis-to-2027-300744837.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store